Skip to content
Screener

Regenxbio RGNX Prepaid & Other Current

Prepaid & Other Current at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$801.7M+39.6%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$105.78M-17.1%
Biogen logo
BiogenBIIB
$1.24B+45.5%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$254.05M+43.4%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$6.38M+2.6%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$14.47M+30.0%

Other financials

Income statement

See full
Revenue$108.0M+406%
Gross profit$14.9M+35.7%
Operating income$29.3M+146%
Net income$22.7M+132%
EPS (diluted)$0.43+131%

Balance sheet

See full
Cash & equivalents$36.5M-54.1%
Total debt$69.0M-11.3%
Total equity$71.8M-66.4%
Total assets$386.6M-33.5%

Cash flow

See full
Operating cash flow-$62.2M-26.1%
CapEx$760.0K+94.4%
Free cash flow-$63.0M-26.7%

Valuation

See full
Market cap$707.66M+87.8%
Enterprise value$740.13M+97.4%
P/S4.1×+1.6×

Profitability

See full
Gross margin59.7%+1.0pp
Operating margin-94.1%-9.3pp
Net margin-112.6%-0.1pp
FCF margin-143.1%-456pp

Returns & leverage

See full
Return on equity-137.6%-817pp
Debt / equity+0.6×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseCurrent.

The source filing: Regenxbio’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:15 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336725
Line itemJune 30, 2026December 31, 2025
Cash and cash equivalents$36,487$34,466
Marketable securities69,030195,604
Accounts receivable106,75426,379
Prepaid expenses11,90411,927
Restricted cash225
Other current assets11,75712,905
Total current assets236,157281,281
Marketable securities10,785

Item 1. Financial Statements.

FAQ

What is Regenxbio's prepaid & other current?
Regenxbio (RGNX) reported prepaid & other current of $11.9M in Q2 2026.
How has Regenxbio's prepaid & other current changed year-over-year?
Regenxbio's prepaid & other current increased by 10.5% year-over-year, from $10.78M to $11.9M.
What is the long-term trend for Regenxbio's prepaid & other current?
Over 5 years (2020 to 2025), Regenxbio's prepaid & other current has grown at a 2.6% compound annual growth rate (CAGR), from $10.51M to $11.93M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.

Ask your AI about Regenxbio's prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude